Immunicum Company
Immunicum is a clinical phase II company, develops cancer immunotherapies.
Technology:
Cell-based gene therapy, Dendritic Cells
Industry:
Dendritic Cells, Public
Headquarters:
Gothenburg, Vastra Gotaland, Sweden
Founded Date:
2002-01-01
Employees Number:
11-50
Funding Status:
IPO
Total Funding:
54604237
Estimated Revenue:
$1M to $10M
Last Funding Date:
2018-10-17
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership